Mental Health Mission Mood Disorder Cohort Study

NCT ID: NCT07189689

Last Updated: 2025-10-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

2000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-10-01

Study Completion Date

2028-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The current study aims to understand why some people with depression respond to treatment and others do not, using markers of clinical symptoms, both clinician reported outcome measures and patient reported outcome measures, demographic information, cognitive function, genetic sequence information (genomic), chemical measures of metabolism (metabolomic), protein makeup (proteomic) and the body's natural defence system (immune/inflammatory markers) together with collections of cells that will facilitate new research to drive improvements in diagnosis and treatment of mood disorders that may be proving difficult to treat. This will allow future clinical trials within the NHS, academia and industry to drive forward new approaches and treatments.

Participants who provide consent for re-contact for future treatment trials and other research studies have the potential to benefit from this with participation in experimental studies and clinical trials associated with improved patient outcomes. Overall, the cohort will generally support greater access to research opportunities for a wider population of people.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depression - Major Depressive Disorder Depression Bipolar Treatment Resistant Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Those aged 18 and above
* Primary clinical diagnosis of MDD or bipolar disorder based on DSM-5/ICD-11 diagnostic criteria
* Participant is willing and able to give informed consent for participation in the study
* Possesses sufficient command of the English language required to complete study requirements, as assessed by the study team

Exclusion Criteria

* Inability to complete study activities as assessed by the study team
* Presentation requires immediate emergency treatment
* Presentation requires clinical input not available within the research clinic
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Newcastle University

OTHER

Sponsor Role collaborator

University of Nottingham

OTHER

Sponsor Role collaborator

University of Exeter

OTHER

Sponsor Role collaborator

University of Southampton

OTHER

Sponsor Role collaborator

University of Birmingham

OTHER

Sponsor Role collaborator

University of Manchester

OTHER

Sponsor Role collaborator

University of Liverpool

OTHER

Sponsor Role collaborator

Avon and Wiltshire Mental Health Partnership NHS Trust

OTHER_GOV

Sponsor Role collaborator

Cambridgeshire and Peterborough NHS Foundation Trust

OTHER

Sponsor Role collaborator

University of Cambridge

OTHER

Sponsor Role collaborator

Cardiff University

OTHER

Sponsor Role collaborator

Cardiff and Vale University Health Board

OTHER_GOV

Sponsor Role collaborator

University of Edinburgh

OTHER

Sponsor Role collaborator

University of Glasgow

OTHER

Sponsor Role collaborator

University College, London

OTHER

Sponsor Role collaborator

Sheffield Health and Social Care NHS Foundation Trust

UNKNOWN

Sponsor Role collaborator

King's College London

OTHER

Sponsor Role collaborator

Imperial College London

OTHER

Sponsor Role collaborator

Oxford Health NHS FT

UNKNOWN

Sponsor Role collaborator

Cumbria, Northumberland, Tyne and Wear NHS FT

UNKNOWN

Sponsor Role collaborator

South London and Maudsley NHS FT

UNKNOWN

Sponsor Role collaborator

Nottinghamshire Healthcare NHS FT

UNKNOWN

Sponsor Role collaborator

Devon Partnership Trust

UNKNOWN

Sponsor Role collaborator

Hampshire and Isle of Wight Health NHS FT

UNKNOWN

Sponsor Role collaborator

Birmingham and Solihull Mental Health NHS Trust

UNKNOWN

Sponsor Role collaborator

Mersey Care NHS FT

UNKNOWN

Sponsor Role collaborator

NHS Lothian

OTHER_GOV

Sponsor Role collaborator

NHS Greater Glasgow & Clyde

UNKNOWN

Sponsor Role collaborator

Camden & Islington NHS FT

UNKNOWN

Sponsor Role collaborator

West London NHS FT

UNKNOWN

Sponsor Role collaborator

Central and North West London NHS FT

UNKNOWN

Sponsor Role collaborator

University of Oxford

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clinical Research Facility, Warneford Hospital

Oxford, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Alexander Lewis

Role: CONTACT

+441865618152

Professor Michael Browning

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Alexander Lewis

Role: primary

+441865618152

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

345799

Identifier Type: OTHER

Identifier Source: secondary_id

18955

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.